Pharos iBio Statistics
Total Valuation
Pharos iBio has a market cap or net worth of KRW 85.70 billion. The enterprise value is 72.94 billion.
Market Cap | 85.70B |
Enterprise Value | 72.94B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Pharos iBio has 12.95 million shares outstanding. The number of shares has increased by 3.87% in one year.
Current Share Class | 12.95M |
Shares Outstanding | 12.95M |
Shares Change (YoY) | +3.87% |
Shares Change (QoQ) | +0.19% |
Owned by Insiders (%) | 32.78% |
Owned by Institutions (%) | 2.72% |
Float | 8.70M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 5.45 |
P/TBV Ratio | 5.61 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -6.89 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -7.72 |
Financial Position
The company has a current ratio of 11.90, with a Debt / Equity ratio of 0.01.
Current Ratio | 11.90 |
Quick Ratio | 11.28 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | -0.01 |
Interest Coverage | -2,547.88 |
Financial Efficiency
Return on equity (ROE) is -51.35% and return on invested capital (ROIC) is -36.74%.
Return on Equity (ROE) | -51.35% |
Return on Assets (ROA) | -35.06% |
Return on Invested Capital (ROIC) | -36.74% |
Return on Capital Employed (ROCE) | -77.57% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.97% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -39.97% |
50-Day Moving Average | 6,702.60 |
200-Day Moving Average | 8,197.30 |
Relative Strength Index (RSI) | 46.37 |
Average Volume (20 Days) | 48,916 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | -17.94M |
Operating Income | -12.21B |
Pretax Income | -10.59B |
Net Income | -10.59B |
EBITDA | -11.40B |
EBIT | -12.21B |
Earnings Per Share (EPS) | -818.86 |
Balance Sheet
The company has 12.85 billion in cash and 84.60 million in debt, giving a net cash position of 12.76 billion or 985.73 per share.
Cash & Cash Equivalents | 12.85B |
Total Debt | 84.60M |
Net Cash | 12.76B |
Net Cash Per Share | 985.73 |
Equity (Book Value) | 15.71B |
Book Value Per Share | 1,213.71 |
Working Capital | 12.54B |
Cash Flow
In the last 12 months, operating cash flow was -8.77 billion and capital expenditures -672.02 million, giving a free cash flow of -9.44 billion.
Operating Cash Flow | -8.77B |
Capital Expenditures | -672.02M |
Free Cash Flow | -9.44B |
FCF Per Share | -729.45 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Pharos iBio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.87% |
Shareholder Yield | n/a |
Earnings Yield | -12.35% |
FCF Yield | -11.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |